Slide 1: Third Quarter 2025 Financial Results
Third Quarter 2025 Financial Results November 6, 2025
Slide 2: Disclaimer
Disclaimer Numerical figures in the presentation have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. In addition, unless otherwise indicated, references to the “Company,” “Cer
Slide 3: Certara Our Mission
Certara Our Mission We use biosimulation, data, and scientific expertise to transform drug development and accelerate medicines to patients. Biosimulation Technology Scientific Leadership Proven Results Platform 20 years of industry leadership More than 90% of all novel drugs More than 2,400 compani
Slide 4: A Trusted Life Sciences Partner
A Trusted Life Sciences Partner 2,600+ 1550+ 400+ >90% Customers across 70 countries; Global team members in Employees with PhDs all novel drugs approved 30 of the top 30 biopharma by the US FDA since 2014 30 countries were supported by Certara solutions Validated by Software adopted by Used by 23 3
Slide 5: Drug Development Needs a New Model
YEAR 15 Drug Development BASIC DRUG PRE- FDA POST- CLINICAL TRIALS RESEARCH DISCOVERY CLINICAL REVIEW APPROVAL Research & Needs a New Model Phase I Phase II Phase III Monitoring 88% OF NEW MEDICINES T H AT E N T E R C L I N I C A L $2–3 BILLION* T R I A L S FA I L* POTENTIAL NEW MEDICINES 1 FDA- 40–
Slide 6: Biosimulation Platform
Biosimulation Platform DISCOVERY PRECLINICAL CLINICAL Integrated chemical and Cheminformatics biological property prediction Biosimulation Integrated workflows for Integrated scientific analytics PK Analytics enhanced cellular predictions and reporting workflows Biostatistical Analytics & Submission
Slide 7: Financial Highlights
Financial Highlights Third Quarter 2025 REVENUE NET INCOME ADJ. EBITDA(2) DILUTED EPS ADJUSTED DILUTED EPS(3) $104.6M $1.5M $35.2M $0.01 $0.14 10% GAAP YoY change PY ($1.4M) 7% YoY PY ($0.01) PY $0.13 10% CC YoY change (1) change (1) See Appendix for reconciliation of GAAP revenue to constant curren
Slide 8: 3Q 2025 Results - Revenue
3Q 2025 Results - Revenue GAAP Reported Revenue Constant Currency Revenue(1) ($Millions) ($Millions) 104.6 104.1 94.8 94.8 60.8 60.5 58.9 58.9 35.9 43.8 35.9 43.6 3Q 2024 3Q 2025 3Q 2024 3Q 2025 Software Services Software Services Certara reported 10% constant currency(1) revenue growth 8 (1) See Ap
Slide 9: 3Q 2025 and TTM Results - Net Bookings
3Q 2025 and TTM Results - Net Bookings 3Q Reported Net Bookings TTM Reported Net Bookings ($Millions) ($Millions) 471.4 419.6 96.1 96.6 283.5 266.3 61.2 55.8 40.8 153.3 187.9 34.9 3Q 2024 3Q 2025 3Q 2024 3Q 2025 Software Services Software Services Trailing twelve months bookings are highly correlate
Slide 10: Historical TTM Book to Bill
Historical TTM Book to Bill ($Millions) $485 1.16x 1.16x 1.16x 1.13x $465 1.13x $445 $425 $405 $385 $365 $345 $325 $305 $285 $265 $245 445.3 457.7 470.8 471.4 $225 419.7 405.8 415.6 $205 372.8 385.1 394.5 $185 $165 $145 $125 $105 $85 $65 $45 $25 3Q 2024 4Q 2024 1Q 2025 2Q 2025 3Q 2025 TTM Bookings T
Slide 11: Historical Software Net Retention Rate (NRR)
Historical Software Net Retention Rate (NRR)(1) 115.0% 114.1% 110.0% 108.6% 108.0% 107.4% 107.6% 107.6% 105.5% 105.0% 103.9% 102.4% 100.0% 3Q 2023 4Q 2023 1Q 2024 2Q 2024 3Q 2024 4Q 2024 1Q 2025 2Q 2025 3Q 2025 NRR(1) provides insight into growth and retention among existing software customers (1) O
Slide 12: 3Q 2025 Results – Adjusted EBITDA
3Q 2025 Results – Adjusted EBITDA Adjusted EBITDA(1) Adjusted EBITDA 35% 33% 33% 31% 34% Margin(1) 33.1 33.5 34.8 31.9 35.2 3Q 2024 4Q 2024 1Q 2025 2Q 2025 3Q 2025 3Q25 Adjusted EBITDA grew 7% vs. the prior year period 12 (1) See Appendix for a reconciliation net income (loss) to adjusted EBITDA
Slide 13: 3Q 2025 Results – Reconciliation of Revenue & Bookings Growth
3Q 2025 Results – Reconciliation of Revenue & Bookings Growth 3Q 2025 Revenue 3Q 2025 Bookings Item Growth Contribution Item Growth Contribution Organic Software(1) +6% Organic Software(1) +5% + Chemaxon ~1560 bps + Chemaxon ~1210 bps Reported Software +22% Reported Software +17% Organic Services(1)
Slide 14: 3Q25 Business Updates
3Q25 Business Updates Key Takeaways from Third Quarter Performance: Solid Execution in Mixed Product Development Investing to Drive Operating Environment Achievements Sustainable Growth • Disciplined operating performance • Launched CertaraIQ and updates to • Continuing to invest in commercial and d
Slide 15: 3Q25 Bookings y/y Trends – Pharma/Biotech Customers
3Q25 Bookings y/y Trends – Pharma/Biotech Customers Tier1 Software Bookings | +17% y/y Services Bookings | (9%) y/y I Solid growth driven by expansion, upsell and strong renewals within existing customers Decline driven by spending hesitancy in biosimulation, softness in regulatory II Declined y/y d
Slide 16: 2025 Outlook
2025 Outlook Updated FY 2025 guidance Key Assumptions 2025 Guidance REVENUE ADJUSTED ADJUSTED EBITDA Margin(1) DILUTED EPS(1) $415-$420M ~32% $0.45-$0.47 Reported revenue growth of 8-9% Chemaxon Revenue expected to be $23-$25M Fully diluted shares expected to be in the range of 160-162M This financi
Slide 17: Appendix
Appendix CERTARAQ
Slide 18: Reconciliation of Net Income (Loss) to Adjusted EBITDA
Reconciliation of Net Income (Loss) to Adjusted EBITDA THREE MONTHS ENDED NINE MONTHS ENDED SEPTEMBER 30, SEPTEMBER 30, 2025 2024 2025 2024 (in thousands) Net income (loss)(a) $ 1,525 $ (1,371) $ 4,300 $ (18,628) Interest expense(a) 5,011 5,187 14,619 16,516 Interest income(a) (1,270) (2,609) (4,155
Slide 19: Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss)
Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss) THREE MONTHS ENDED NINE MONTHS ENDED SEPTEMBER 30, SEPTEMBER 30, 2025 2024 2025 2024 ( in thousands) Net income (loss) (a) $ 1,525 $ (1,371) $ 4,300 $ (18,628) Currency (gain) loss(a) (534) 1,546 (1,173) 2,526 Equity-based compensatio
Slide 20: Reconciliation of Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share
Reconciliation of Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share THREE MONTHS ENDED NINE MONTHS ENDED SEPTEMBER 30, SEPTEMBER 30, 2025 2024 2025 2024 Diluted earnings per share(a) $ 0.01 $ (0.01) $ 0.03 $ (0.12) Currency (gain) loss(a) - 0.01 - 0.02 Equity-based compensation expen
Slide 21: Reconciliation of Revenues to the Revenues Adjusted for Constant Currency
Reconciliation of Revenues to the Revenues Adjusted for Constant Currency THREE MONTHS ENDED SEPTEMBER 30, Change 2025 2025 2024 $ % $ % Actual CC Actual Actual Actual CC Impact (GAAP) (non-GAAP) (GAAP) (GAAP) (GAAP) (non-GAAP) (non-GAAP) (in thousands except percentage) Revenue Software $ 43,830 $
Slide 22: Notes to Reconciliations
Notes to Reconciliations a) Represents a measure determined under GAAP. b) Represents expense related to equity-based compensation. Equity-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation st
Slide 23: Accelerating Medicines, Together
Accelerating Medicines, Together